Level 1, Suite 12
Lake Macquarie Oncology6-8 Sydney St
Gateshead, NSW, 2290 Get Directions
(02) 4947 5762
02 4947 5765
Claim your profile
Dr Hiren Mandaliya is a fellow of The Royal Australasian College of Physicians. Dr Mandaliya also has a special interest in cancer research.
Following attainment of his fellowship, Dr Mandaliya joined Calvary Mater Newcastle as Clinical Trial Fellow to broaden his research experience and while there he works with leading clinicians, scientists and researchers in the field.
In his current role, he has been involved in multiple Phase I, Phase II and Phase III trials as sub-investigator. Dr Mandaliya has a strong commitment to medical education and is affiliated as a Conjoint lecturer with the University of Newcastle.
He is also an active member of Future Leaders Group of Hunter Cancer Research Alliance (HCRA). Dr Mandaliya completed his MBBS and MD (Internal Medicine) in India and came to Australia in 2009.
He completed his fellowship training in Medical Oncology (FRACP) at Calvary Mater Newcastle, North West Cancer Centre (Tamworth) and Macarthur Cancer Therapy Centre.
Dr Mandaliya has conducted research projects for breast, lung, gastrointestinal and other malignancies. His research work and interests have also focused on psychosocial aspects of cancer survivors and medical students’ education.
He has presented his research results at various local, national and international conferences such as ASCO (American Society of Clinical Oncology) and ESMO (European Society of Medical Oncology).
Dr Mandaliya has also published his research in various peer-reviewed journals. Dr Mandaliya has a broad interest in the management of malignancies such as gastrointestinal, gynaecological, genitourinary, lung, melanoma, breast and head & neck.
Dr Mandaliya is a regular member of the multidisciplinary tumour board meeting at John Hunter Hospital and Calvary Mater Newcastle.
He is a member of Medical Oncology Group of Australia (MOGA), the Australasian Gastro-Intestinal Trials Group (AGITG), Breast Cancer Trials group, ASCO and ESMO.